Approval, Evidence, and “Off-Label” Device Utilization: The Patent Foramen Ovale Closure Story
Circulation: Cardiovascular Quality and Outcomes · 2024
DOI: 10.1161/circoutcomes.123.010200 ↗Kurz gefasst
Fachartikel in der Zeitschrift Circulation: Cardiovascular Quality and Outcomes, 2024. Verfasst von Andrew M Goldsweig und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Baystate Medical Center, Springfield, MA (A.M.G.). Hauptthemen laut MEDLINE: Foramen Ovale, Patent, Atrial Fibrillation, Stroke, Ischemic Attack, Transient. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NCATS NIH HHS, NIGMS NIH HHS.
Abstract (Originalsprache)
BACKGROUND: Following regulatory approval, medical devices may be used “off-label.” Patent foramen ovale (PFO) closure is indicated to reduce recurrent stroke but has been proposed for other indications, including migraine, transient ischemic attack, and diving decompression illness. We sought to evaluate PFO closure rates and indications relative to the timing of regulatory approval and publication of key randomized trials. METHODS: We performed a retrospective cohort study using the OptumLabs Data Warehouse of US commercial insurance enrollees from 2006 to 2019. We quantified PFO closure among individuals with ≥2 years of preprocedure coverage to establish indications, classified hierarchically as stroke/systemic embolism, migraine, transient ischemia attack, or other. RESULTS: We identified 5315 patients undergoing PFO closure (51.8% female, 29.2%≥60 years old), which increased from 4.75 per 100 000 person-years in 2006 to 6.60 per 100 000 person-years in 2019. Patients aged ≥60 years accounted for 29.2% of closures. Procedure volumes corresponded weakly with supportive clinical publications and device approval. Among patients with PFO closure, 58.6% underwent closure for stroke/systemic embolism, 10.2% for transient ischemia attack, 8.8% for migraine, and 22.4% for other indications; 17.6% of patients had atrial fibrillation at baseline; and 11.9% developed atrial fibrillation postprocedure. Those aged ≥60 years and male were less likely to undergo closure for migraine than stroke/systemic embolism. CONCLUSIONS: From 2006 to 2019, PFO closure use was consistently low and corresponded weakly with clinical trial publications and regulatory status. Nearly half of patients underwent PFO closure for indications unapproved by the Food and Drug Administration. Regulators and payers should coordinate mechanisms to promote utilization for approved indications to ensure patient safety and should facilitate clinical trials for other possible indications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiovascular Medicine, Baystate Medical Center, Springfield, MA (A.M.G.).
- Kern Center for the Science of Health Care Delivery and Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (Y.D., X.Y., S.T.S.).
- Section of Cardiovascular Medicine, Yale University, New Haven, CT (N.R.D., A.J.L.).
- Cardiovascular Research Foundation, New York, NY (D.J.C.).
- St. Francis Hospital and Heart Center, Roslyn, NY (D.J.C.).
- Department of Cardiovascular Medicine, Henry Ford Health System, Detroit, MI (H.D.A.).
ORCID-Profile: Andrew M Goldsweig, Xiaoxi Yao, Nihar R Desai, David J Cohen, Herbert D Aronow, Steven R Messé, Joseph S Ross, Alexandra J Lansky, Samuel T Savitz
Förderung
- NHLBI NIH HHS
- NCATS NIH HHS
- NIGMS NIH HHS
- AHRQ HHS
- FDA HHS
Zitieren
APA
Goldsweig, A. M., Deng, Y., Yao, X., Desai, N. R., Cohen, D. J., Aronow, H. D., Messé, S. R., Ross, J. S., Lansky, A. J., & Savitz, S. T. (2024). Approval, Evidence, and “Off-Label” Device Utilization: The Patent Foramen Ovale Closure Story. Circulation: Cardiovascular Quality and Outcomes. https://doi.org/10.1161/circoutcomes.123.010200
Vancouver
Goldsweig AM, Deng Y, Yao X, Desai NR, Cohen DJ, Aronow HD, et al. Approval, Evidence, and “Off-Label” Device Utilization: The Patent Foramen Ovale Closure Story. Circulation: Cardiovascular Quality and Outcomes. 2024. doi:10.1161/circoutcomes.123.010200
BibTeX
@article{Goldsweig2024,
author = {Goldsweig, Andrew M and Deng, Yihong and Yao, Xiaoxi and Desai, Nihar R and Cohen, David J and Aronow, Herbert D and Messé, Steven R and Ross, Joseph S and Lansky, Alexandra J and Savitz, Samuel T},
title = {Approval, Evidence, and “Off-Label” Device Utilization: The Patent Foramen Ovale Closure Story},
journal = {Circulation: Cardiovascular Quality and Outcomes},
year = {2024},
doi = {10.1161/circoutcomes.123.010200}
}
EUVIMED